S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:YMAB

Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News

$18.96
+0.52 (+2.82%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$17.83
▼
$19.10
50-Day Range
$10.80
▼
$19.67
52-Week Range
$6.50
▼
$39.82
Volume
407,600 shs
Average Volume
576,089 shs
Market Capitalization
$828.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.83

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
62.6% Upside
$30.83 Price Target
Short Interest
Bearish
9.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Y-mAbs Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.70) to ($1.46) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

737th out of 1,283 stocks

Pharmaceutical Preparations Industry

355th out of 615 stocks

See Top Rated MarketRank™ Stocks Here
YMAB stock logo

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Y-mAbs Therapeutics Trading Up 2.8 %

NASDAQ:YMAB traded up $0.52 during trading hours on Friday, reaching $18.96. The company had a trading volume of 407,625 shares, compared to its average volume of 276,570. Y-mAbs Therapeutics has a 1-year low of $6.50 and a 1-year high of $39.82. The business's 50 day moving average price is $15.27 and its 200-day moving average price is $11.91.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.07. The business had revenue of $10.49 million during the quarter, compared to analysts' expectations of $11.10 million. Y-mAbs Therapeutics had a negative return on equity of 59.67% and a negative net margin of 291.89%. The business's revenue was up 94.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. As a group, analysts forecast that Y-mAbs Therapeutics will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. BMO Capital Markets assumed coverage on Y-mAbs Therapeutics in a report on Thursday, June 23rd. They set an "outperform" rating and a $27.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $63.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, April 29th. Finally, Wedbush decreased their price target on Y-mAbs Therapeutics from $28.00 to $21.00 and set an "outperform" rating for the company in a report on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.83.

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

August 4, 2022 | americanbankingnews.com
Contrasting Tricida (NASDAQ:TCDA) and Y-mAbs Therapeutics (NASDAQ:YMAB)
August 2, 2022 | finance.yahoo.com
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
August 8, 2022 | Legacy Research (Affiliate) (Ad)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
July 31, 2022 | americanbankingnews.com
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.5%
July 28, 2022 | americanbankingnews.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $30.83 Consensus PT from Analysts
July 12, 2022 | finance.yahoo.com
Y-mAbs’ Announces Clearance of IND for GD2-SADA
June 30, 2022 | finance.yahoo.com
Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 57% loss from investing in the stock a year ago
June 1, 2022 | barrons.com
Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS(R) (omburtamab) for the Treatment of Neuroblastoma for Priority Review
August 8, 2022 | Legacy Research (Affiliate) (Ad)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
May 31, 2022 | seekingalpha.com
Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 31, 2022 | seekingalpha.com
Y-mAbs Omblastys gets FDA priority review to treat children with nerve cell cancer
May 31, 2022 | finance.yahoo.com
Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review
May 26, 2022 | finance.yahoo.com
Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint
May 14, 2022 | seekingalpha.com
Y-mAbs Therapeutics, Inc. (YMAB) CEO Thomas Gad on Q1 2022 Results - Earnings Call Transcript
May 10, 2022 | marketwatch.com
Y-mAbs Shares Gain 20% on 1Q Revenue Increase and Company Guidance
May 9, 2022 | finance.yahoo.com
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
May 9, 2022 | investing.com
Y-mAbs Therapeutics Tops Q1 EPS by 8c
May 3, 2022 | finance.yahoo.com
Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
April 28, 2022 | finance.yahoo.com
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
April 27, 2022 | seekingalpha.com
Y-mAbs Therapeutics says CEO to quit, issues Danyelza revenue guidance
April 27, 2022 | finance.yahoo.com
Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update
April 8, 2022 | finance.yahoo.com
Y-mAbs Announces Presentation of SADA Technology at AACR
April 1, 2022 | marketwatch.com
Y-mAbs Therapeutics Shares Rise 10% After Resubmitting Biologics License Application
April 1, 2022 | baystreet.ca
Y-mAbs Jumps on News from Lab
April 1, 2022 | seekingalpha.com
Y-mAbs resubmits U.S. marketing application for omburtamab to FDA
April 1, 2022 | finance.yahoo.com
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
March 7, 2022 | finance.yahoo.com
What Kind Of Shareholders Hold The Majority In Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares?
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Company Calendar

Last Earnings
11/04/2021
Today
8/08/2022
Next Earnings (Confirmed)
8/08/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMAB
CUSIP
N/A
CIK
1722964
Web
www.ymabs.com
Phone
(646) 885-8505
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.83
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+62.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,280,000.00
Net Margins
-291.89%
Pretax Margin
-291.89%
Return on Equity
-59.67%
Return on Assets
-51.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.12
Quick Ratio
5.93

Sales & Book Value

Annual Sales
$34.90 million
Price / Sales
23.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
4.59

Miscellaneous

Outstanding Shares
43,714,000
Free Float
31,789,000
Market Cap
$828.82 million
Optionable
Not Optionable
Beta
1.15

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price forecast for 2022?

6 Wall Street analysts have issued 12 month price targets for Y-mAbs Therapeutics' stock. Their YMAB stock forecasts range from $21.00 to $63.00. On average, they predict Y-mAbs Therapeutics' share price to reach $30.83 in the next year. This suggests a possible upside of 62.6% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics or view top-rated stocks among Wall Street analysts.

How has Y-mAbs Therapeutics' stock performed in 2022?

Y-mAbs Therapeutics' stock was trading at $16.21 at the beginning of the year. Since then, YMAB stock has increased by 17.0% and is now trading at $18.96.
View the best growth stocks for 2022 here.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Y-mAbs Therapeutics.

How can I listen to Y-mAbs Therapeutics' earnings call?

Y-mAbs Therapeutics will be holding an earnings conference call on Tuesday, August 9th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its quarterly earnings results on Monday, May, 9th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.07. The firm earned $10.49 million during the quarter, compared to analysts' expectations of $11.10 million. Y-mAbs Therapeutics had a negative net margin of 291.89% and a negative trailing twelve-month return on equity of 59.67%. The firm's quarterly revenue was up 94.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.75 EPS.

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $67.81 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Connor Clark & Lunn Investment Management Ltd. (0.08%), Strs Ohio (0.06%), SG Americas Securities LLC (0.04%), State Board of Administration of Florida Retirement System (0.03%), DnB Asset Management AS (0.03%) and Mirae Asset Global Investments Co. Ltd. (0.03%). Company insiders that own Y-mAbs Therapeutics stock include Biotech Aps Wg, Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $18.96.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $828.74 million and generates $34.90 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 148 workers across the globe.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for Y-mAbs Therapeutics is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.